Drugs / MART-1 antigen
MART-1 antigen
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02320305 | Jan → Dec 2015 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT01748747 | Oct 2012 → Dec 2014 | melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT00470015 | Mar 2007 → Apr 2009 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00037037 | Oct 2001 → ? | cutaneous melanoma | Herbert Irving Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 1 | NCT00005841 | Jun → Dec 2000 | cutaneous melanoma, ocular melanoma | University of Southern California | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00002952 | Jan 1997 → Aug 2002 | cutaneous melanoma | University of Chicago | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00303836 | Nov 2005 → Jan 2007 | metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00089063 | Jun 2004 → Jun 2007 | iris melanoma, medium/large size posterior uveal melanoma, ocular melanoma with extraocular extension | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00031733 | Feb 2002 → Dec 2004 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT00020475 | Feb 2001 → Mar 2007 | ocular melanoma with extraocular extension | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019994 | Oct 1999 → Oct 2007 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00019721 | Apr 1999 → Jun 2003 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00091338 Background | Aug 2004 → ? | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00025181 Background | Oct 2001 → Jan 2003 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MART-1 antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00031733 ↗ |
| Known as | MART-1 | “The melanoma tumor antigen epitope peptides MART-1(26-35 (27L)), gp100(209-217 (210M)),and tyrosinase(368-376 (370D)) were emulsified with incomplete Freund's adjuvant and...” PMID 12684398 ↗ Apr 2003 |
| Known as | MART-1a | “melanoma-associated peptide (MART-1a)” PMID 32752904 ↗ Aug 2020 |
| Action | Deplete | “Vaccines made from peptides may make the body build an immune response to kill tumor cells.” NCT00089063 ↗ |
| Modality | Vaccine | “melanoma peptide vaccine comprising tyrosinase:368-376 peptide, gp100:209-217 antigen, and MART-1:26-35 antigen emulsified in Montanide ISA-51” NCT00005841 ↗ |
| Route | Subcutaneous | “Patients receive melanoma peptide vaccine comprising tyrosinase:368-376 peptide, gp100:209-217 antigen, and MART-1:26-35 antigen emulsified in Montanide ISA-51 subcutaneously...” NCT00005841 ↗ |